Physician profile
Shaker Barham
NPI 1366825077
$11,145.16
in general payments reported to CMS, 2019-2025
38 companies · $3,743 in 2025
The $3,743 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $356 · 2021: $1,209 · 2022: $1,112 · 2023: $1,643 · 2024: $2,948 · 2025: $3,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,509 · Travel and Lodging: $3,719 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,509.09 |
| Travel and Lodging | $3,719.02 |
| Education | $105.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,446.64 | 2021-2025 | Axios, Spyglass, Exalt Model D |
| Olympus Corporation of The Americas | $2,254.51 | 2024-2025 | Single Use Electrosurgical Knife Kd-655, Disposable Distal Attachment, Olympus |
| Abbvie INC. | $1,497.70 | 2020-2025 | Skyrizi, Rinvoq, Creon |
| Gilead Sciences, INC. | $309.90 | 2019-2025 | |
| Lilly USA, LLC | $252.80 | 2023-2025 | Omvoh |
| Janssen Biotech, INC. | $237.43 | 2023-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $204.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Amgen INC. | $195.68 | 2025 | Uplizna |
| Olympus America INC. | $166.39 | 2022-2024 | Visiglide, Endoclot Phs |
| Medtronic, INC. | $155.50 | 2022-2023 | Gi Genius, Prodigi |
| Lumendi LLC | $147.00 | 2025 | |
| Eisai INC. | $112.26 | 2020 | |
| Celgene Corporation | $103.44 | 2023-2024 | Zeposia |
| Alcresta Therapeutics, INC. | $99.65 | 2023 | Relizorb |
| Ardelyx, INC. | $90.28 | 2022-2024 | Ibsrela |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaker Barham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.